TY - JOUR T1 - Comparison of Serum Level and IL-18 Gene Expression and Reactive Protein in Patients with Type 2 Diabetes with Metabolic Syndrome and Healthy People TT - مقایسه سطح سرمی و بیان ژن اینترلوکین 18 و پروتئین واکنشگر C‌در بیماران دیابت نوع دو مبتلا به سندرم متابولیک و افراد سالم JF - sjimu JO - sjimu VL - 27 IS - 3 UR - http://sjimu.medilam.ac.ir/article-1-5113-en.html Y1 - 2019 SP - 173 EP - 182 KW - Interleukin 18 KW - C-reactive protein KW - Type II diabetes KW - Metabolic syndrome N2 - Introduction: Metabolic syndrome is a common clinical anomaly, with an increased risk of developing type 2 diabetes and cardiovascular risk factors. Increased inflammatory mediators, such as reactive protein,as well as the inflammatory cytokines can be associated with the incidence and progression of metaboli syndrome and type 2 diabetes. Materials & Methods: This study was performed on 35 male and female patients with an average age of 55 years, type 2 diabetes mellitus with metabolic syndrome and 35 healthy subjects as control group. Separated serum samples were kept at -20 ° C for quantitative evaluation of serum IL-18 by ELISA kit and C-reactive protein. RNA extraction from cells was performed by JenaBioscience kit and finally Gene expression assay was performed quantitatively using Real Time RTPCR. Findings: The mean serum levels of IL-18 were significantly increased (P=0.008), and serum reactive protein (P<0.001) was significantly increased in patients with type 2 diabetes mellitus with metabolic syndrome compared with healthy subjects. Also, expression of IL-18 gene (P=0.003) in lymphocyte cells of type II diabetes patients with metabolic syndrome was significantly higher than healthy subjects. Discussion & Conclusions: The present study showed that patients with type 2 diabetes mellitus with metabolic syndrome have high levels of inflammatory factors such as IL-18 in their serum. it can be concluded that serum levels of IL-18, C-reactive protein and IL-18 expression play an important role in inflammatory response and progression. Type 2 diabetes and metabolic syndrome. M3 10.29252/sjimu.27.3.173 ER -